DE69434008D1 - Botulinustoxin zur Behandlung Muskelkrankheiten verbundenen Schmerzen - Google Patents

Botulinustoxin zur Behandlung Muskelkrankheiten verbundenen Schmerzen

Info

Publication number
DE69434008D1
DE69434008D1 DE69434008T DE69434008T DE69434008D1 DE 69434008 D1 DE69434008 D1 DE 69434008D1 DE 69434008 T DE69434008 T DE 69434008T DE 69434008 T DE69434008 T DE 69434008T DE 69434008 D1 DE69434008 D1 DE 69434008D1
Authority
DE
Germany
Prior art keywords
botulinum toxin
related pain
treat muscle
toxin used
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434008T
Other languages
English (en)
Other versions
DE69434008T2 (de
Inventor
K Roger Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434008(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of DE69434008D1 publication Critical patent/DE69434008D1/de
Application granted granted Critical
Publication of DE69434008T2 publication Critical patent/DE69434008T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69434008T 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen Expired - Lifetime DE69434008T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28
US173996 1993-12-28

Publications (2)

Publication Number Publication Date
DE69434008D1 true DE69434008D1 (de) 2004-10-21
DE69434008T2 DE69434008T2 (de) 2005-09-22

Family

ID=22634387

Family Applications (23)

Application Number Title Priority Date Filing Date
DE122009000038C Pending DE122009000038I1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434319T Expired - Lifetime DE69434319T3 (de) 1993-12-28 1994-12-16 Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen
DE69428813T Expired - Lifetime DE69428813T2 (de) 1993-12-28 1994-12-16 Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69434511T Expired - Lifetime DE69434511T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von Dystonie
DE69433394T Expired - Lifetime DE69433394T3 (de) 1993-12-28 1994-12-16 Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69435302T Expired - Lifetime DE69435302D1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435321T Expired - Lifetime DE69435321D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69434540T Expired - Lifetime DE69434540T2 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435330T Expired - Lifetime DE69435330D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69435243T Expired - Lifetime DE69435243D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69435249T Expired - Lifetime DE69435249D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69435276T Expired - Lifetime DE69435276D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie
DE69434008T Expired - Lifetime DE69434008T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
DE69427869T Expired - Lifetime DE69427869T2 (de) 1993-12-28 1994-12-16 Botulinumtoxine zur behandlung von hyperhydrosis
DE69435194T Expired - Lifetime DE69435194D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434610T Expired - Lifetime DE69434610T2 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69434443T Revoked DE69434443T2 (de) 1993-12-28 1994-12-16 Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435270T Expired - Lifetime DE69435270D1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434535T Revoked DE69434535T2 (de) 1993-12-28 1994-12-16 Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69435116T Expired - Lifetime DE69435116D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122008000043C Pending DE122008000043I1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435149T Expired - Lifetime DE69435149D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE122008000042C Pending DE122008000042I1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen

Family Applications Before (12)

Application Number Title Priority Date Filing Date
DE122009000038C Pending DE122009000038I1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434319T Expired - Lifetime DE69434319T3 (de) 1993-12-28 1994-12-16 Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen
DE69428813T Expired - Lifetime DE69428813T2 (de) 1993-12-28 1994-12-16 Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69434511T Expired - Lifetime DE69434511T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von Dystonie
DE69433394T Expired - Lifetime DE69433394T3 (de) 1993-12-28 1994-12-16 Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69435302T Expired - Lifetime DE69435302D1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435321T Expired - Lifetime DE69435321D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69434540T Expired - Lifetime DE69434540T2 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435330T Expired - Lifetime DE69435330D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69435243T Expired - Lifetime DE69435243D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69435249T Expired - Lifetime DE69435249D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69435276T Expired - Lifetime DE69435276D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie

Family Applications After (10)

Application Number Title Priority Date Filing Date
DE69427869T Expired - Lifetime DE69427869T2 (de) 1993-12-28 1994-12-16 Botulinumtoxine zur behandlung von hyperhydrosis
DE69435194T Expired - Lifetime DE69435194D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434610T Expired - Lifetime DE69434610T2 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69434443T Revoked DE69434443T2 (de) 1993-12-28 1994-12-16 Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435270T Expired - Lifetime DE69435270D1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434535T Revoked DE69434535T2 (de) 1993-12-28 1994-12-16 Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69435116T Expired - Lifetime DE69435116D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122008000043C Pending DE122008000043I1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435149T Expired - Lifetime DE69435149D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE122008000042C Pending DE122008000042I1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen

Country Status (9)

Country Link
EP (23) EP1477183B1 (de)
JP (33) JP3238154B2 (de)
AU (1) AU688452B2 (de)
CA (2) CA2682117A1 (de)
DE (23) DE122009000038I1 (de)
ES (18) ES2355491T3 (de)
FR (1) FR08C0034I1 (de)
HK (6) HK1033274A1 (de)
WO (1) WO1995017904A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE122009000066I2 (de) 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1477183B1 (de) * 1993-12-28 2005-11-02 Allergan, Inc. Toxisches komponent der Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
EP0758900B1 (de) * 1994-05-09 2002-04-10 BINDER, William J. Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
AU2006225233C1 (en) * 1997-07-15 2011-02-10 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
JP3692033B2 (ja) * 1997-07-15 2005-09-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
EP1053014A4 (de) 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGISCH AKTIVES HÄMAGGLUTININ VOM TYP A i(STRIDIUM BOTULINUM) UNDVERFAHREN ZU SEINER VERWENDUNG
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6649161B1 (en) * 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
AU2001276005A1 (en) * 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CA2501856A1 (en) * 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1599221B1 (de) * 2003-03-06 2011-12-28 Botulinum Toxin Research Associates, Inc. Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin
WO2004078199A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
AU2005215521A1 (en) * 2004-02-12 2005-09-01 Radovic, Phillip Treatment of abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
NZ592041A (en) * 2004-03-03 2012-12-21 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1747782A1 (de) 2005-07-19 2007-01-31 Cesare Montecucco Produkte zur topischen Anwendung enthaltend Lysophospholipide und Fettsäuren
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
AU2006315117A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007095486A1 (en) * 2006-02-13 2007-08-23 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
EP2134257A4 (de) 2007-03-30 2014-03-05 Anders Fagergren Quantifizierung von mechanischen und neuralen beiträgen zur spastizität
NZ582459A (en) 2007-07-26 2012-05-25 Revance Therapeutics Inc Antimicrobial peptide, compositions, and methods of use
EP2072039A1 (de) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
SG10202100698QA (en) 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
IL268980B (en) 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
KR101677710B1 (ko) * 2014-06-30 2016-11-21 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3436054B2 (de) * 2016-09-13 2022-07-27 Allergan, Inc. Stabilisierte proteinfreie clostridientoxinzusammensetzungen
EP3843777A4 (de) * 2018-08-28 2022-05-04 Ira Sanders Therapeutika für die haut
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
WO2022075785A1 (ko) * 2020-10-07 2022-04-14 주식회사 프로톡스 보툴리눔 독소의 진공 건조 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
JP4381477B2 (ja) * 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド 筋膜疼痛症候群の治療方法
DE122009000066I2 (de) * 1993-06-10 2010-12-30 Allergan Inc Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1477183B1 (de) * 1993-12-28 2005-11-02 Allergan, Inc. Toxisches komponent der Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0758900B1 (de) * 1994-05-09 2002-04-10 BINDER, William J. Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
JP2002087988A (ja) 2002-03-27
HK1064599A1 (en) 2005-02-04
ES2319860T3 (es) 2009-05-14
JP2010209105A (ja) 2010-09-24
EP1563843B1 (de) 2013-08-07
JP2002097156A (ja) 2002-04-02
DE69435302D1 (de) 2010-08-26
ES2340172T3 (es) 2010-05-31
DE69435149D1 (de) 2008-11-20
JP2012167115A (ja) 2012-09-06
DE69428813T2 (de) 2002-04-04
ES2207910T5 (es) 2010-05-21
DE69435321D1 (de) 2010-12-16
JP2002068989A (ja) 2002-03-08
EP1366770B1 (de) 2005-07-27
JP2002104990A (ja) 2002-04-10
EP1103267B1 (de) 2004-09-15
DE69434535T2 (de) 2006-07-20
EP1591129B1 (de) 2010-02-24
AU1516295A (en) 1995-07-17
WO1995017904A3 (en) 1995-10-19
EP1591129A3 (de) 2005-11-16
HK1106700A1 (en) 2008-03-20
DE69434443D1 (de) 2005-09-01
JP2002087987A (ja) 2002-03-27
DE122009000038I1 (de) 2009-11-05
ES2309973T3 (es) 2008-12-16
EP1147775A3 (de) 2003-01-15
EP1366770A2 (de) 2003-12-03
EP1502600B1 (de) 2009-10-07
EP1010431B1 (de) 2005-03-30
EP1790352B1 (de) 2008-07-09
EP1366771A2 (de) 2003-12-03
EP1502600A1 (de) 2005-02-02
EP1147776B1 (de) 2010-12-15
ES2248780T3 (es) 2008-06-16
EP1005867A3 (de) 2001-06-13
DE69434319T2 (de) 2006-03-09
JP2013006865A (ja) 2013-01-10
EP1010431B2 (de) 2010-07-14
EP1477183A1 (de) 2004-11-17
EP1147775B1 (de) 2009-03-04
DE69435270D1 (de) 2010-04-01
EP0770395B1 (de) 2001-10-24
DE69435243D1 (de) 2009-11-19
EP1010431A3 (de) 2001-05-16
EP1421948A2 (de) 2004-05-26
EP1790352A1 (de) 2007-05-30
EP1147775A2 (de) 2001-10-24
JPH09507234A (ja) 1997-07-22
DE69427869T2 (de) 2002-04-11
DE69434319D1 (de) 2005-05-04
DE69434610D1 (de) 2008-08-21
EP1757325B1 (de) 2010-11-03
JP2002097145A (ja) 2002-04-02
EP0737074A1 (de) 1996-10-16
EP2027872B1 (de) 2010-07-14
ES2223393T3 (es) 2005-03-01
ES2334357T3 (es) 2010-03-09
ES2347384T3 (es) 2010-10-28
DE69434511T2 (de) 2006-07-13
DE69435330D1 (de) 2011-01-27
DE69433394T3 (de) 2010-08-12
FR08C0034I1 (fr) 2008-09-26
ES2163090T3 (es) 2002-01-16
EP1366771A3 (de) 2003-12-10
JP2006160756A (ja) 2006-06-22
DE69434511D1 (de) 2006-03-02
EP1602379A1 (de) 2005-12-07
EP1147776A2 (de) 2001-10-24
HK1033274A1 (en) 2001-08-24
EP1598077A1 (de) 2005-11-23
EP1072270A3 (de) 2002-08-07
JP2008037877A (ja) 2008-02-21
EP1147776A3 (de) 2003-01-15
JP2010202660A (ja) 2010-09-16
DE69428813D1 (de) 2001-11-29
EP2027872A1 (de) 2009-02-25
DE69435116D1 (de) 2008-08-21
CA2682117A1 (en) 1995-07-06
EP1486214A1 (de) 2004-12-15
JP2012167114A (ja) 2012-09-06
EP0770395A1 (de) 1997-05-02
DE69434535D1 (de) 2005-12-08
EP1757325A1 (de) 2007-02-28
JP2008063339A (ja) 2008-03-21
DE69434610T2 (de) 2008-11-27
DE69435276D1 (de) 2010-04-08
JP2012188433A (ja) 2012-10-04
JP2002087984A (ja) 2002-03-27
EP1010431A2 (de) 2000-06-21
DE69434540T2 (de) 2009-06-18
JP2010202661A (ja) 2010-09-16
ES2355491T3 (es) 2011-03-28
ES2237033T5 (es) 2010-10-29
ES2332905T3 (es) 2010-02-15
HK1072375A1 (en) 2005-08-26
ES2237033T3 (es) 2005-07-16
DE69435194D1 (de) 2009-04-16
JP2012167117A (ja) 2012-09-06
EP1563843A1 (de) 2005-08-17
JP3238154B2 (ja) 2001-12-10
CA2180011C (en) 2001-05-15
EP1488803A1 (de) 2004-12-22
CA2180011A1 (en) 1995-07-06
DE69427869D1 (de) 2001-09-06
JP2012167116A (ja) 2012-09-06
JP2008031176A (ja) 2008-02-14
EP1072270B1 (de) 2005-10-19
JP2002087986A (ja) 2002-03-27
ES2242126T3 (es) 2005-11-01
EP1366770A3 (de) 2004-03-17
JP2002087985A (ja) 2002-03-27
EP1600163B1 (de) 2010-02-17
EP1477183B1 (de) 2005-11-02
JP2008056683A (ja) 2008-03-13
DE69435249D1 (de) 2009-12-17
EP1005867A2 (de) 2000-06-07
EP1421948A3 (de) 2004-06-16
DE69434008T2 (de) 2005-09-22
ES2339865T3 (es) 2010-05-26
AU688452B2 (en) 1998-03-12
JP2010202659A (ja) 2010-09-16
ES2247575T3 (es) 2006-03-01
JP2002104991A (ja) 2002-04-10
JP2006160754A (ja) 2006-06-22
ES2246800T3 (es) 2006-03-01
EP1005867B2 (de) 2010-02-17
EP1072270A2 (de) 2001-01-31
EP1600163A1 (de) 2005-11-30
DE69434319T3 (de) 2011-02-17
EP1103267A1 (de) 2001-05-30
DE69433394D1 (de) 2004-01-15
ES2251651T3 (es) 2008-07-16
DE69434540D1 (de) 2009-03-26
EP1598077B1 (de) 2009-11-04
DE69433394T2 (de) 2004-10-14
WO1995017904A2 (en) 1995-07-06
JP2012197287A (ja) 2012-10-18
HK1071071A1 (en) 2005-07-08
DE122008000043I1 (de) 2008-11-20
EP1488803B1 (de) 2008-03-26
DE122008000042I1 (de) 2009-01-02
DE69434443T2 (de) 2006-05-24
ES2159624T3 (es) 2001-10-16
EP1591129A2 (de) 2005-11-02
HK1070831A1 (en) 2005-06-30
EP1421948B1 (de) 2008-10-08
JP2002114706A (ja) 2002-04-16
EP0737074B1 (de) 2001-08-01
EP1005867B1 (de) 2003-12-03
EP1366771B1 (de) 2008-03-26
JP2008056682A (ja) 2008-03-13
JP2006160755A (ja) 2006-06-22
ES2207910T3 (es) 2004-06-01
JP2006160753A (ja) 2006-06-22
JP2007262086A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
DE69434008D1 (de) Botulinustoxin zur Behandlung Muskelkrankheiten verbundenen Schmerzen
DE69630947D1 (de) Mittel zur schmerzbehandlung
ATA46794A (de) Einrichtung zur behandlung von hautzonen
BR9407799A (pt) Composição de matéria método de tratamento e composição farmaceutica
ATE480253T1 (de) Verwendung von botulinum toxin zur behandlung von gelenkschmerzen
KR960702274A (ko) 메디컬 신호를 증대시키는 방법 및 시스템 (method and system to enhance medical signals)
DE59406123D1 (de) Haarbehandlungsmittel
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DK91793A (da) Fremgangsmåde til overfladebehandling, midler til udøvelse og anvendelsen heraf
DE69506019D1 (de) Vorrichtung zur Behandlung von Schmerz
DK73891D0 (da) Enzymbehandling
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DK0577086T3 (da) Fremgangsmåde til overfladebehandling
DK0594528T3 (da) Fremgangsmåde og anlæg til behandling af halve slagtekroppe
NO941014D0 (no) Jordbehandlingsprosess
DE69306260D1 (de) Behandlung von abwasser
ATE189388T1 (de) Biologisch aktive ureido-derivate nützlich zur behandlung von multipler sklerose
LU84488A1 (de) Mittel zur behandlung von akne
DK289388D0 (da) Desinfektionsmiddel til at desinficere hud og overflader paa genstande
DE69311802D1 (de) Verfahren zur metallbehandlung
FI961883A0 (fi) Jäteveden puhdistusmenetelmä
ATA86593A (de) Behandlungsanlage
SE9004160D0 (sv) Method of treating pain

Legal Events

Date Code Title Description
8363 Opposition against the patent